Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Second Quarter Glaucoma Franchise Net Revenues of $33.3 Million, up 23% over Second Quarter 2021Outlook for Net Cash Used Expected to Be Less Than $20 Million per Quarter, on Average, for the Remainder of 2022  Aerie Expects to be Cash Flow Break Even During 2024DURHAM, N.C.DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharm...

Related Keywords

United States ,Raj Kannan ,Hans Vitzthum ,Carolyn Mcauliffe ,Aerie Pharmaceuticals Inc ,Drug Administration ,Nasdaq ,Regulatory Agency ,Exchange Commission ,European Medicines Agency ,Aerie Pharmaceuticals ,Second Quarter Glaucoma Franchise Net Revenues ,Second Quarter ,Net Cash Used Expected ,Cash Flow Break Even During ,Chief Executive Officer ,Quarter Financial Results ,Pipeline Objectives ,New Drug Application ,Webcast Information ,Call Time ,Dial In Time ,Private Securities Litigation Reform Act ,Investigational New Drug Applications ,Loss Per Share ,Adjusted Net Loss Per Share ,Sci Advisors ,